A study that investigated the prognostic role of baseline IL-8 under sorafenib treatment in a Japanese HCC cohort, in which 86.7% of the patients had viral hepatitis, showed no correlation between baseline IL-8 levels and treatment response or survival (Miyahara et al. 2011). This evidence concerns the gene CXCL8 and hepatocellular carcinoma.